Table 3.
Analysis of the association between thrombocytosis and clinicopathological parameters of endometrial carcinoma
| Clinicopathological characteristics | Number of studies | Model | OR (95% CI) | I2 (%) | P h | Z | P |
|---|---|---|---|---|---|---|---|
| FIGO stage (III-IV vs. I-II) | 5 | Random | 3.24 (1.78–5.88) | 58.1 | 0.049 | 3.86 | < 0.001 |
| Grade (2–3 vs.1) | 6 | Fixed | 1.89 (1.30–2.76) | 19.4 | 0.287 | 3.32 | 0.001 |
| LVSI (yes vs. no) | 5 | Fixed | 1.98 (1.34–2.94) | 0 | 0.603 | 3.4 | 0.001 |
| Histological type (non-endometrioid vs. endometrioid) | 5 | Random | 1.45 (0.76–2.77) | 60.6 | 0.038 | 1.11 | 0.265 |
| LN metastasis (yes vs. no) | 2 | Fixed | 3.13 (1.71–5.75) | 0 | 0.416 | 3.69 | < 0.001 |
| Recurrence (yes vs. no) | 2 | Fixed | 8.57 (3.71–19.83) | 0 | 0.458 | 5.02 | < 0.001 |
| VTE (yes vs. no) | 2 | Fixed | 6.45 (4.06–10.24) | 0 | 0.807 | 7.91 | < 0.001 |
Random-effects model was used when P-value for heterogeneity test < 0.1; otherwise, fixed-effects model was used
Abbreviations: FIGO International Federation of Gynecology and Obstetrics, LVSI lymphovascular space invasion, LN lymph node, VTE venous thromboembolism, OR odds ratio, CI confidence interval, Ph, P-value for heterogeneity based on Q test, P P-value for statistical significance based on Z test